Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

A heart team at King Faisal Specialist Hospital & Research Center (KFSHRC) in Riyadh, Saudi Arabia, made a bit of history, completing the world’s first fully robotic heart transplant. The procedure, which lasted roughly two and half hours, was performed on a 16-year-old patient with end-stage heart failure. One reason this patient was selected was the fact that he had specifically requested the heart team not open his chest.

Surgeons make history, perform world’s first fully robotic heart transplant

The procedure, which lasted roughly two and half hours, was performed on a 16-year-old patient with end-stage heart failure. 

Implantable Barostim device improves long-term heart failure symptoms

The FDA-approved device helps regulate the heart, kidneys and vascular system by targeting sensors in a patient's carotid artery. 

cross market hospital mergers

Abiomed, Biosense Webster, Cerenovus now all known as Johnson & Johnson MedTech

These companies were already part of the Johnson & Johnson family, but they had still retained their previous brand names. Now, each one is officially going by Johnson & Johnson MedTech. 

HFSA 2023 image courtesy of the Heart Failure Society of America

HFSA announces late-breaking research for 2024 annual meeting

In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time.

AISAP, an Israeli healthcare technology company focused on using artificial intelligence (AI) to enhance medical imaging results, has gained U.S. Food and Drug Administration (FDA) clearance for its new point-of-care ultrasound (POCUS) software platform, AISAP Cardio.

FDA clears AI-powered POCUS platform for structural heart disease, heart failure

The cloud-based platform was designed to help even inexperienced users scan and diagnose a majority of common heart issues within minutes without leaving the patient’s side.

HeartMate 3 LVAD abbott

No aspirin, no problem: FDA approves key update for Abbott heart pumps

Patients have typically been told to take aspirin and an oral anticoagulant following treatment to help combat the risk of blood clots. Now, they can skip the aspirin altogether.

V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.

Johnson & Johnson to acquire heart failure specialists V-Wave for up to $1.7B

V-Wave has gained considerable attention for its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and lungs of HFrEF patients.

CMR of a patient showing evidence of myocardial hypertrophy

MRI results help cardiologists predict heart failure risk

"This breakthrough suggests that heart MRI could potentially replace invasive diagnostic tests," one specialist said. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup